Capricor Shares Surge 77% as Potential FDA Approval Revives Hopes for Duchenne Drug Treatment

Capricor Therapeutics experienced a significant stock surge of 77% following the announcement that the U.S. Food and Drug Administration (FDA) would review new data related to its experimental drug for Duchenne muscular dystrophy, deramiocel. This surge comes after a previous downturn when an FDA advisory panel had overwhelmingly voted against the drug’s efficacy based on its effectiveness data. Concerns raised by the panel included methodological changes in trial outcome measurement and uncertainty regarding whether patients actually exhibited Duchenne-related cardiomyopathy, given their baseline heart function.

In light of these developments, Capricor’s CEO, Linda Marban, indicated that the company plans to submit an amendment that includes 24-month data aimed at enhancing upper limb muscle function, which is the primary objective of its late-stage study. Notably, certain panel members had shown more openness to the treatment’s impact on arm and hand function despite skepticism towards its cardiac benefits. The FDA’s willingness to reconsider Capricor’s submission could indicate a more favorable regulatory outlook than previously anticipated, particularly as the agency stated it would extend its decision deadline upon receiving the new information.

Analysts are beginning to view this regulatory pivot positively, with Roth Capital suggesting that the FDA’s resubmission could classify as a “major amendment,” which would likely extend the review period by approximately three months. This shift could provide Capricor with crucial time to substantiate its claims regarding the drug’s effectiveness. Furthermore, Capricor’s financial position remains robust, with $237.9 million in cash reported at the end of June, allowing it to strategically manage commercial launch spending while awaiting regulatory developments.

Overall, the recent resurgence in Capricor’s stock highlights a potential turnaround in sentiment among investors, with analysts from Cantor noting the FDA’s decision to review new data as a potentially positive surprise. Oppenheimer analysts echoed this sentiment, suggesting that this apparent regulatory pivot strengthens the case for potential approval, presenting a clear opportunity for investors to reevaluate the company’s long-term viability.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)